Prevalence and genotype screening of human papillomavirus among women attending a private hospital in Northern Cyprus: an 11-year retrospective study.
Pregnancy
Female
Humans
Human Papillomavirus Viruses
Papillomavirus Infections
/ diagnosis
Uterine Cervical Neoplasms
/ diagnosis
Retrospective Studies
Cyprus
/ epidemiology
Prevalence
Papillomaviridae
/ genetics
Human papillomavirus 16
/ genetics
DNA, Viral
/ genetics
Genotype
Hospitals, Private
Uterine Cervical Dysplasia
/ diagnosis
Cervical cancer
Cyprus
Genotyping
High-risk HPV
Human papillomavirus
Real-time PCR
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
03 06 2023
03 06 2023
Historique:
received:
24
03
2023
accepted:
25
05
2023
medline:
5
6
2023
pubmed:
4
6
2023
entrez:
3
6
2023
Statut:
epublish
Résumé
Human papillomavirus (HPV) is the most common sexually transmitted pathogen both in men and women. Accumulating epidemiological evidence supports a strong association between HPV infection and cancer of the cervix, vulva, vagina, anus, and penis. Currently, data on the HPV prevalence and genotyping is lacking in Northern Cyprus, a region in which HPV vaccination is not freely accessible via the national immunization program. The aim of this study was to evaluate the HPV type-specific prevalence in women with and without cytological abnormalities living in Northern Cyprus. A total of 885 women who presented to the Department of Gynecology and Obstetrics Clinic between January 2011 and December 2022 were included in the study. Samples were collected for cytology. Cervical specimens were investigated for the presence of HPV-DNA and genotyping of HPV was performed using real-time polymerase chain reaction (rtPCR). Cytological examination was interpreted according to the Bethesda system. Among all patients, overall high-risk HPV DNA prevalence was 44.3%. HPV-16 and HPV-18 positivity was found in 10.4% and 3.7% of women respectively, while other high-risk HPV (OHR-HPV) was the most frequent type of HPV (30.2%). The highest frequency of HPV infection was observed in the 30-55 age group (51.0%), followed by the < 30 age group (45.7%). Co-infection with two or more HPV types was observed in 17.0% of all positive samples, in which the prevalence of HPV-16 + HPV-18 was 2.3%, HPV-16 + OHR-HPV and HPV-18 + OHR-HPV was 12.0% and 5.1%, respectively. Among the screened patients, 37.5% had abnormal and 62.5% had normal cytology results. HR-HPV positivity was 65.7% and 34.0% in patients with abnormal and normal cytology. The highest incidence of HRC-HPV was OHR-HPV types (44.7%) in positive cytology cases. Among women with a cytology result of ASCUS, L-SIL, H-SIL and unspecified dysplasia, 52.1%, 67.6%, 97.5% and 75.6% were respectively infected with HR-HPV. The present study provides the latest epidemiological data related to HPV prevalence and genotype distribution among women living in Northern Cyprus. Considering the unavailability of free vaccination in the community, it is imperative to implement local HPV screening programs and provide guidelines on HPV prevention and measures during early school education.
Sections du résumé
BACKGROUND
Human papillomavirus (HPV) is the most common sexually transmitted pathogen both in men and women. Accumulating epidemiological evidence supports a strong association between HPV infection and cancer of the cervix, vulva, vagina, anus, and penis. Currently, data on the HPV prevalence and genotyping is lacking in Northern Cyprus, a region in which HPV vaccination is not freely accessible via the national immunization program. The aim of this study was to evaluate the HPV type-specific prevalence in women with and without cytological abnormalities living in Northern Cyprus.
METHODS
A total of 885 women who presented to the Department of Gynecology and Obstetrics Clinic between January 2011 and December 2022 were included in the study. Samples were collected for cytology. Cervical specimens were investigated for the presence of HPV-DNA and genotyping of HPV was performed using real-time polymerase chain reaction (rtPCR). Cytological examination was interpreted according to the Bethesda system.
RESULTS
Among all patients, overall high-risk HPV DNA prevalence was 44.3%. HPV-16 and HPV-18 positivity was found in 10.4% and 3.7% of women respectively, while other high-risk HPV (OHR-HPV) was the most frequent type of HPV (30.2%). The highest frequency of HPV infection was observed in the 30-55 age group (51.0%), followed by the < 30 age group (45.7%). Co-infection with two or more HPV types was observed in 17.0% of all positive samples, in which the prevalence of HPV-16 + HPV-18 was 2.3%, HPV-16 + OHR-HPV and HPV-18 + OHR-HPV was 12.0% and 5.1%, respectively. Among the screened patients, 37.5% had abnormal and 62.5% had normal cytology results. HR-HPV positivity was 65.7% and 34.0% in patients with abnormal and normal cytology. The highest incidence of HRC-HPV was OHR-HPV types (44.7%) in positive cytology cases. Among women with a cytology result of ASCUS, L-SIL, H-SIL and unspecified dysplasia, 52.1%, 67.6%, 97.5% and 75.6% were respectively infected with HR-HPV.
CONCLUSION
The present study provides the latest epidemiological data related to HPV prevalence and genotype distribution among women living in Northern Cyprus. Considering the unavailability of free vaccination in the community, it is imperative to implement local HPV screening programs and provide guidelines on HPV prevention and measures during early school education.
Identifiants
pubmed: 37270608
doi: 10.1186/s12905-023-02451-8
pii: 10.1186/s12905-023-02451-8
pmc: PMC10239278
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297Informations de copyright
© 2023. The Author(s).
Références
Vaccines (Basel). 2023 Mar 18;11(3):
pubmed: 36992282
Ecancermedicalscience. 2019 Jul 25;13:952
pubmed: 31552125
Asian Pac J Cancer Prev. 2021 Sep 01;22(9):2969-2976
pubmed: 34582669
Cold Spring Harb Perspect Biol. 2013 Jul 01;5(7):
pubmed: 23685995
PLoS One. 2019 Jan 17;14(1):e0210311
pubmed: 30653566
Vaccines (Basel). 2020 Jul 16;8(3):
pubmed: 32708759
J Pathol. 2014 Dec;234(4):431-5
pubmed: 25124771
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Virol J. 2023 Jan 18;20(1):11
pubmed: 36653807
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3373-3377
pubmed: 29286606
Cancer. 2021 Nov 01;127(21):4030-4039
pubmed: 34368955
Cancer Manag Res. 2020 Dec 08;12:12583-12591
pubmed: 33324103
Ecancermedicalscience. 2019 Nov 20;13:978
pubmed: 31921349
Int J Environ Res Public Health. 2022 Jan 08;19(2):
pubmed: 35055515
J Med Virol. 2022 Oct;94(10):5026-5032
pubmed: 35676203
Int J Environ Res Public Health. 2022 Sep 15;19(18):
pubmed: 36141917
J Infect. 2013 Mar;66(3):207-17
pubmed: 23103285
PLoS One. 2020 Feb 21;15(2):e0229154
pubmed: 32084177
J Infect Dis. 2011 Apr 1;203(7):910-20
pubmed: 21402543
BMC Womens Health. 2023 Feb 16;23(1):70
pubmed: 36793099
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prev Med. 2022 Mar;156:106960
pubmed: 35065979
Front Microbiol. 2022 Jun 30;13:914516
pubmed: 35847094
BMC Infect Dis. 2017 May 16;17(1):346
pubmed: 28511636
Int J Environ Res Public Health. 2022 Oct 13;19(20):
pubmed: 36293758
Vaccines (Basel). 2022 Apr 09;10(4):
pubmed: 35455328
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Exp Ther Med. 2020 Dec;20(6):186
pubmed: 33101476
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Lancet. 2021 Dec 4;398(10316):2084-2092
pubmed: 34741816
Int J Infect Dis. 2014 Dec;29:226-31
pubmed: 25447728
Obstet Gynecol. 2020 Sep;136(3):533-542
pubmed: 32769648
Front Microbiol. 2018 Nov 28;9:2896
pubmed: 30546351